[1] Peng X, Li T, Xia E,et al. A comparison of oestrogen receptor and progesterone receptor expression in endomet rial polypsand endometrium of premenopausal women[J]. J Obstet Gynaecol, 2009, 29(4): 340-346.
[2] Gul A, Ugur M, Iskender C, et al. Immunohistochemical expression of estrogen and progestero ne receptors in endometrial polypsand its relationship to clinical parameters[J]. Arch Gynecol Obstet, 2010, 281(3): 479-483.
[3] de Carvalho S, Campaner A B, Lima S M, et al. Differential expression of estrogen and progesterone receptors in endometrial polyps and adjacent endometrium in postmenopausal women[J]. Anal Quant Cytol Histol, 2011, 33(2): 61-67.
[4] Erdemoglu E, Güney M, Karahan N, et al. Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignantpolyps of the endometrium [J]. Eur J Gynaecol Oncol, 2008, 29(5): 444-449.
[5] Cigdem T, Fatma A, Fatma D, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-2 in adenomyosis and endometrial polyps and its correlation with angiogenesis [J]. Int J Gynecol Pathol, 2009, 28(2): 148-156.
[6] Markovitch O, Tepper R, Fishman A, et al. Long-term “protective” effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients [J]. Breast Cancer Res Treat, 2009, 113(2): 321-326.
[7] Pal L, Niklaus A L, Kim M, et al. Heterogeneity in endometrial expression of aromatase in polyp-bearing uteri[J]. Hum Reprod,2008, 23(1): 80-84.
[8] Xuebing P, TinChiu L, Enlan X,et al. Is endometrial polyp formation associated with increased expression of vascular endothelial growth factor and transforming growth factor-beta1?[J] . Eur J Obstet Gynecol Reprod Biol, 2011,159(1): 198-203.
[17] Baiocchi G, Manci N, Pazzaglia M,et al. Malignancy inendometrialpolyps: a 12-year experience[J]. Am J Obstet Gynecol,2009, 201(5): 462.e1-4.
[18] Wang J H, Zhao J, Lin J. Opportunities and risk factors for premalignant and malignant transformation of endometrialpolyps: management strategies [J]. J Minim Invasive Gynecol,2010,17(1): 53-58.